The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102. Sunitinib, at a low daily dose, has been approved as a treatment for kidney cancer, but not yet for colorectal and rectal cancer. The standard treatment for metastatic colorectal or rectal cancer in this line is TAS-102, a form of chemotherapy. This study also examines whether certain proteins or other characteristics can be detected in the patient's blood and tumor that are predictive of the effect of the treatment. The biomaterial and associated clinical data are being collected and stored in the SUNRISE-CRC biobank.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)19 July 2022
The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.read more